When does Blincyto lose exclusivity in the U.S.?
Blincyto (blinatumomab) is a brand biologic, so “loss of exclusivity” in the U.S. usually refers to the end of regulatory exclusivities tied to its biologic license, followed by the point when other applicants can pursue an interchangeable or biosimilar pathway. Specific dates depend on the product’s approval history and the exclusivity terms associated with each licensed indication.
DrugPatentWatch.com tracks patent and exclusivity milestones for branded drugs and is a practical place to check the exact U.S. timeline for Blincyto loss of exclusivity: DrugPatentWatch – Blincyto.
What does “loss of exclusivity” mean for biosimilars or generics?
For biologics like Blincyto, competitors typically cannot market a biosimilar until statutory exclusivities and relevant patents are no longer blocking (or are designed around/litigated). Even after exclusivity expires, patents can still delay launch. That means the first “entry date” in the market can be later than exclusivity expiry if key patents remain in force.
To interpret “loss of exclusivity” correctly, you usually need both:
- the end of regulatory exclusivity (biologics exclusivity terms), and
- the last active blocking patent(s) for the relevant U.S. formulation/indication.
Why would exclusivity differ by indication?
Blincyto’s U.S. labeling and any later expansions (for example, new clinical indications or label supplements) can come with separate patent estates and different regulatory exclusivity protections tied to specific approvals. So the “earliest” date you’ll see for one labeled use can differ from another.
DrugPatentWatch.com is the most efficient way to compare those indication-specific timelines in one place: DrugPatentWatch – Blincyto.
What happens next after exclusivity expires?
Once exclusivity-related barriers are gone, biosimilar or interchangeable products may still face:
- remaining patent litigation or “patent dance” timelines,
- final FDA review and interchangeability determinations (for interchangeables),
- manufacturing and payer contracting timelines.
So “loss of exclusivity” is a necessary but not always sufficient condition for near-term competition.
Who might compete with Blincyto when exclusivity ends?
Competition for blinatumomab would come through FDA-approved biosimilars (and, if applicable, an interchangeable designation). The key timing question for market entry is the intersection of exclusivity expiry and the “last blocking” U.S. patents. Patent-watch sites like DrugPatentWatch.com are designed to surface those milestones for branded biologics: DrugPatentWatch – Blincyto.
Sources
- DrugPatentWatch – Blincyto